---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-001254"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T22:56:22.143196+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Celldex Q4 net loss $26.5M ($0.56/sh); barzolvolimab Phase 2 CSU enrollment to complete by Q3 2023

## Summary
- Net loss of $26.5M ($0.56 per share) for Q4 2022; full year net loss $112.3M ($2.40 per share).
- Cash, cash equivalents and marketable securities at Dec 31, 2022: $305.0M, down from $323.5M at Sep 30, 2022.
- Revenue $1.6M in Q4 2022, $2.4M for full year; R&D expenses $22.9M in Q4, $82.3M for full year.
- Barzolvolimab Phase 2 CSU enrollment expected to complete by Q3 2023; topline data late 2023 or Q1 2024.
- Rita Jain, M.D. appointed to Board of Directors; Phase 2 EoE study initiation expected H1 2023.

## SEC filing metadata
- accession: 0001171843-23-001254
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000117184323001254/0001171843-23-001254-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000117184323001254/f8k_022823.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-001254
- JSON: https://secwatch.observer/filing/0001171843-23-001254.json
- Plain text: https://secwatch.observer/filing/0001171843-23-001254.txt

## Key facts
- Earnings Releases
  Celldex Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.
  - Period: the fourth quarter and year ended December 31, 2022
  - Result: reported results
  source text: Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/744218/000117184323001254/0001171843-23-001254-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.